Evaluation of safety and analgesic consumption in patients with advanced cancer treated with zoledronic acid

1. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001; 27: 165-76.10.1053/ctrv.2000.0210Search in Google Scholar

2. Rajer M, Kovač V. Malignant spinal cord compression. Radiol Oncol 2008; 42: 23-31.10.2478/v10019-007-0035-4Search in Google Scholar

3. Gojkovič Horvat A, Kovač V, Strojan P. Radiotherapy in palliative treatment of painful bone metastases. Radiol Oncol 2009; 43: 213-24.Search in Google Scholar

4. Maillefert JF, Sibilia J, Michel F, Saussine C, Javier RM, Tavernier C. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 1999; 161: 1219-22.10.1016/S0022-5347(01)61639-2Search in Google Scholar

5. Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. JUrol 2000; 163: 181-6.Search in Google Scholar

6. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458-68.10.1093/jnci/94.19.145812359855Search in Google Scholar

7. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. JNatl Cancer Inst 2004; 96: 879-82.10.1093/jnci/djh14115173273Search in Google Scholar

8. Aapro M, Saad F. Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid. Ther Adv Urol 2012; 4: 85-101.10.1177/1756287212441234331754422496711Search in Google Scholar

9. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011; 59: 572-83.10.1016/j.eururo.2011.01.02521315502Search in Google Scholar

10. Anderson KC, Alsina M, Bensinger W, Biermann JS, Cohen AD, Steven Devine S, et al. NCCN Guidelines version 1.2013. Multiple Myeloma. J Natl ComprCanc Netw 2013; 11: 11-7.10.6004/jnccn.2013.000423307977Search in Google Scholar

11. Tamburrelli FC, Proietti L, Scaramuzzo L, De Stefano V, Logroscino CA. Bisphosphonate therapy in multiple myeloma in preventing vertebral collapses: preliminary report. Eur Spine J 2012; 21(Suppl 1): S141-5.10.1007/s00586-012-2231-1332539922434531Search in Google Scholar

12. Mhaskar R, Redzepovic J, Wheatley K, Clark OAC, Miladinovic B, Glasmacher A, et al. Bisphosphonates in multiple myeloma: a network meta-analysis. Cochrane Database Syst Rev 2012; 5: CD003188.10.1002/14651858.CD003188.pub322592688Search in Google Scholar

13. Mohler, JL, Armstrong AJ, Bahnson RR, Boston B, Busby EJ, D’Amico AV, et al. Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. JNatl Compr Canc Netw 2012; 10: 1081-710.6004/jnccn.2012.0114Search in Google Scholar

14. NCI Common Terminology Criteria for Adverse Events (CTCAE) v.4 data files. Availabele 15th February, 2013: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40Search in Google Scholar

15. Peddi P, Lopez-Olivo MA, Pratt GF, Suarez-Almazor ME. Denosumab in patients with cancer and skeletal metastases: a systematic review and metaanalysis. Cancer Treat Rev 2013; 39: 97-104.10.1016/j.ctrv.2012.07.002Search in Google Scholar

16. Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377: 813-22.10.1016/S0140-6736(10)62344-6Search in Google Scholar

17. Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011; 29: 1125-32.10.1200/JCO.2010.31.330421343556Search in Google Scholar

18. Serpa Neto A, Tobias-Machado M, Esteves MA, Senra MD, Wroclawski ML, Fonseca FLA, et al. Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and metaanalysis. Prostate Cancer Prostatic Dis 2012; 15: 36-44.10.1038/pcan.2011.421894175Search in Google Scholar

19. Polascik TJ, Given RW, Metzger C, Julian SR, Vestal JC, Karlin GS, et al. Openlabel trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases. Urology 2005; 66: 1054-9.10.1016/j.urology.2005.05.03516286123Search in Google Scholar

20. Pouessel D, Culine S. Complete clinical and biological response to zoledronic acid in castrate-resistant prostate cancer metastatic to bone. AnticancerDrugs 2012; 23: 141-2.10.1097/CAD.0b013e32834bede521934600Search in Google Scholar

21. Coleman R, Cook R, Hirsh V, Major P, Lipton A. Zoledronic acid use in cancer patients: more than just supportive care? Cancer 2011; 117: 11-23.Search in Google Scholar